Pub Date : 2019-01-01DOI: 10.20902/ijptr.2019.120406
Deshmukh Madhuri D, Deshmukh Supriya D
A simple, rapid, accurate, precise, specific and economical spectrophotometric method for simultaneous estimation of Cilnidipine and Valsartan in combined tablet dosage form has been developed. Its employs Formation and solving of simultaneous equation using two wavelengths 240.20nm and 250nm using methanol as solvent. This method obeys Beers law in the employed concentration range 2-12μg /mL and 8-40 μg /mL for Cilnidipine and Valsartan respectively. Coefficient of correlation (R2) was 0.999for Cilnidipine and 0.999 for Valsartan. This method can be adopted in routine analysis of Cilnidipine and Valsartan in bulk and tablet dosage form and it involves relatively low cost solvent and no complex extraction technique.
{"title":"Development and Validation of UV Spectrophotometric\u0000Method for the Estimation of Cilnidipine and Valsartan in\u0000Bulk and Pharmaceutical Formulations","authors":"Deshmukh Madhuri D, Deshmukh Supriya D","doi":"10.20902/ijptr.2019.120406","DOIUrl":"https://doi.org/10.20902/ijptr.2019.120406","url":null,"abstract":"A simple, rapid, accurate, precise, specific and economical spectrophotometric method for simultaneous estimation of Cilnidipine and Valsartan in combined tablet dosage form has been developed. Its employs Formation and solving of simultaneous equation using two wavelengths 240.20nm and 250nm using methanol as solvent. This method obeys Beers law in the employed concentration range 2-12μg /mL and 8-40 μg /mL for Cilnidipine and Valsartan respectively. Coefficient of correlation (R2) was 0.999for Cilnidipine and 0.999 for Valsartan. This method can be adopted in routine analysis of Cilnidipine and Valsartan in bulk and tablet dosage form and it involves relatively low cost solvent and no complex extraction technique.","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87599084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20902/IJPTR.2019.120108
Safni Marlina, A. P. Ketaren, C. A. Andra, H. Hasan, A. N. Nasution, Y. Sarastri
Background: Right ventricular function is an important evaluation in echocardiography assessment. Right ventricular function has important prognostic and therapeutic implications especially in heart failure. Right ventricular performance defines the prognosis in patients with heart failure but the assessment still has challenge because of its complex geometry and the interrelationship with the left ventricle. Right Ventricle Outflow Tract Fractional Shortening (RVOT FS) is a new parameter echocardiography, simple and easy to evaluate right ventricular function in patients with heart failure. Methods: This is a cross sectional study of 84 patients heart failure who has ejection fraction < 50% and undergo routine echocardiography in Haji Adam Malik Hospital since August 2018 until October 2018. RVOT FS was measured by M-mode from parasternal short-axis view at aortic valve level with magnified images of RVOT, and the cursor was aligned perpendicular to the anterior RVOT wall. Then, we measured RVOT end-diastolic (RVOT ED) and RVOT end-systolic (RVOT ES) diameters. Results: The cut-off value of RVOT FS <25.5 was 88.4% sensitive and 82.9% specific to identify patients with impaired RV function in patients with heart failure. There was positive correlation between RVOT FS, TAPSE and S’ with RV FAC. TAPSE has strongest correlation with RV FAC (r= 0.788, P<0.001), S’ also showed positive correlation with RV FAC (r= 0.703, P< 0.001) and RVOT FS (r= 0.644, P<0.001).Conclusion : The results of this study show that the values of RVOT FS can be used as a new parameter echocardiography for assessment right ventricular function in patients with systolic heart failure. Keyword : Right Ventricular Outflow Tract (RVOT), Right Ventricle, Systolic Heart Failure. Safni Marlina et al /International Journal of PharmTech Research, 2019,12(1): 57-62. DOI: http://dx.doi.org/10.20902/IJPTR.2019.120108 ***** International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304, ISSN(Online): 2455-9563 Vol.12, No.01, pp 57-62, 2019
{"title":"Right Ventricular Outflow Tract Fractional Shortening (RVOT FS) As Echocardiography Parameter for Assessment Right Ventricular Function in Systolic Heart Failure","authors":"Safni Marlina, A. P. Ketaren, C. A. Andra, H. Hasan, A. N. Nasution, Y. Sarastri","doi":"10.20902/IJPTR.2019.120108","DOIUrl":"https://doi.org/10.20902/IJPTR.2019.120108","url":null,"abstract":"Background: Right ventricular function is an important evaluation in echocardiography assessment. Right ventricular function has important prognostic and therapeutic implications especially in heart failure. Right ventricular performance defines the prognosis in patients with heart failure but the assessment still has challenge because of its complex geometry and the interrelationship with the left ventricle. Right Ventricle Outflow Tract Fractional Shortening (RVOT FS) is a new parameter echocardiography, simple and easy to evaluate right ventricular function in patients with heart failure. Methods: This is a cross sectional study of 84 patients heart failure who has ejection fraction < 50% and undergo routine echocardiography in Haji Adam Malik Hospital since August 2018 until October 2018. RVOT FS was measured by M-mode from parasternal short-axis view at aortic valve level with magnified images of RVOT, and the cursor was aligned perpendicular to the anterior RVOT wall. Then, we measured RVOT end-diastolic (RVOT ED) and RVOT end-systolic (RVOT ES) diameters. Results: The cut-off value of RVOT FS <25.5 was 88.4% sensitive and 82.9% specific to identify patients with impaired RV function in patients with heart failure. There was positive correlation between RVOT FS, TAPSE and S’ with RV FAC. TAPSE has strongest correlation with RV FAC (r= 0.788, P<0.001), S’ also showed positive correlation with RV FAC (r= 0.703, P< 0.001) and RVOT FS (r= 0.644, P<0.001).Conclusion : The results of this study show that the values of RVOT FS can be used as a new parameter echocardiography for assessment right ventricular function in patients with systolic heart failure. Keyword : Right Ventricular Outflow Tract (RVOT), Right Ventricle, Systolic Heart Failure. Safni Marlina et al /International Journal of PharmTech Research, 2019,12(1): 57-62. DOI: http://dx.doi.org/10.20902/IJPTR.2019.120108 ***** International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304, ISSN(Online): 2455-9563 Vol.12, No.01, pp 57-62, 2019","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90625191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20902/ijptr.2019.120209
William Wiryawan, Otman Siregar, Pranajaya Dharma Kadar, Heru Rahmadhany, Benny
Patient presented with paraparesis of the arm after sustaining a motorvehicle accident. XRay Cervical showed type II odontoid fracture. Tetraparesis has been reported to be associated with fracture of axis and/ or atlas and acute CCS has rarely been associated with the fractures. However, this case illustrated patient with central cord syndrome asscociated with odontoid fracture. MRI of the cervical spine has revealed lesion consistent with the acute central cord syndrome at C2-C3 level. Treatment with gallie method has shown lower fusion rate than screw rod construct. Patient underwent posterior atlantoaxial fusion with screw rod construct and was discharged with a good neurological improvement.
{"title":"Case Report: Odontoid Fracture Anderson and D’Alonzo Type II Associated with Central Cord Syndrome","authors":"William Wiryawan, Otman Siregar, Pranajaya Dharma Kadar, Heru Rahmadhany, Benny","doi":"10.20902/ijptr.2019.120209","DOIUrl":"https://doi.org/10.20902/ijptr.2019.120209","url":null,"abstract":"Patient presented with paraparesis of the arm after sustaining a motorvehicle accident. XRay Cervical showed type II odontoid fracture. Tetraparesis has been reported to be associated with fracture of axis and/ or atlas and acute CCS has rarely been associated with the fractures. However, this case illustrated patient with central cord syndrome asscociated with odontoid fracture. MRI of the cervical spine has revealed lesion consistent with the acute central cord syndrome at C2-C3 level. Treatment with gallie method has shown lower fusion rate than screw rod construct. Patient underwent posterior atlantoaxial fusion with screw rod construct and was discharged with a good neurological improvement.","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91497307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20902/IJPTR.2019.120203
Petrus S. Pinem, C. A. Andra, A. N. Nasution, H. Hasan, A. Siregar, T. B. Haykal
Background: The prolonged QT interval and QT dispersion are ECG markers associated with the incidence of ventricular arrhythmias, and cardiovascular mortality in patients with acute myocardial infarction. This study aims to examine whether QT dispersion can be used as a predictor of the severity of lesions in STEMI patients in Haji Adam Malik General Hospital. Methods: A total of 68 patients with STEMI who undergo coronary angiography at Haji Adam Malik General Hospital since Januari 2018 until December 2018 were recruited in this cross sectional study. QT dispersion was counted from the first ECG when patient admitted at the emergency room. And then coronary angiography was done, and the Gensini score was calculated as a parameter of coronary lesion severity.Results: In the ROC curve analysis, the cut-off value of QT dispersion in the prediction of severe coronary lesion was 80.5 (AUC 0.874, 95% CI 0.778-0.970, p<0.001). The STEMI group with QT dispersion ≥ 80.5 had a higher incidence of severe coronary lesion than the group with QT dispersion < 80.5 of 34 people (89.5%) versus 4 people (10.5%). QT dispersion ≥ 80.5 is considered to predict the severity of coronary lesion with a sensitivity of 89.5%, a specificity of 83.3%, a negative predictive value (NPV) of 86.2% and a positive predictive value (PPV) of 87.1%. Conclusion: QT dispersion is a simple, very useful and an inexpensive indicator which may be used as a predictor for coronary lesion severity in patients with STEMI.
背景:QT间期延长和QT离散度是与急性心肌梗死患者室性心律失常发生率和心血管病死率相关的心电图指标。本研究旨在研究QT离散度是否可以作为Haji Adam Malik总医院STEMI患者病变严重程度的预测因子。方法:本横断面研究共招募了2018年1月至2018年12月在哈吉亚当马利克综合医院接受冠状动脉造影的68例STEMI患者。QT离散度从患者入住急诊室时的第一次心电图开始计数。然后进行冠状动脉造影，计算Gensini评分作为冠状动脉病变严重程度的参数。结果:在ROC曲线分析中，QT离散度预测严重冠状动脉病变的临界值为80.5 (AUC 0.874, 95% CI 0.778 ~ 0.970, p<0.001)。QT离散度≥80.5 STEMI组34人(89.5%)比QT离散度< 80.5组4人(10.5%)发生严重冠状动脉病变的发生率高。QT离散度≥80.5被认为预测冠状动脉病变严重程度的敏感性为89.5%，特异性为83.3%，阴性预测值(NPV)为86.2%，阳性预测值(PPV)为87.1%。结论:QT离散度是一种简单、实用且价格低廉的指标，可作为STEMI患者冠状动脉病变严重程度的预测指标。
{"title":"QT Dispersion as a Predictor of Coronary Lesion Severity in ST-Elevation Myocardial Infarction","authors":"Petrus S. Pinem, C. A. Andra, A. N. Nasution, H. Hasan, A. Siregar, T. B. Haykal","doi":"10.20902/IJPTR.2019.120203","DOIUrl":"https://doi.org/10.20902/IJPTR.2019.120203","url":null,"abstract":"Background: The prolonged QT interval and QT dispersion are ECG markers associated with the incidence of ventricular arrhythmias, and cardiovascular mortality in patients with acute myocardial infarction. This study aims to examine whether QT dispersion can be used as a predictor of the severity of lesions in STEMI patients in Haji Adam Malik General Hospital. Methods: A total of 68 patients with STEMI who undergo coronary angiography at Haji Adam Malik General Hospital since Januari 2018 until December 2018 were recruited in this cross sectional study. QT dispersion was counted from the first ECG when patient admitted at the emergency room. And then coronary angiography was done, and the Gensini score was calculated as a parameter of coronary lesion severity.Results: In the ROC curve analysis, the cut-off value of QT dispersion in the prediction of severe coronary lesion was 80.5 (AUC 0.874, 95% CI 0.778-0.970, p<0.001). The STEMI group with QT dispersion ≥ 80.5 had a higher incidence of severe coronary lesion than the group with QT dispersion < 80.5 of 34 people (89.5%) versus 4 people (10.5%). QT dispersion ≥ 80.5 is considered to predict the severity of coronary lesion with a sensitivity of 89.5%, a specificity of 83.3%, a negative predictive value (NPV) of 86.2% and a positive predictive value (PPV) of 87.1%. Conclusion: QT dispersion is a simple, very useful and an inexpensive indicator which may be used as a predictor for coronary lesion severity in patients with STEMI.","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79971127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20902/IJPTR.2019.120103
Vinayender Adireddy, V. Kommineni, V. Ponneri
The aim of this work was to develop a simple,sensitive and selective liquid chromatography tandem mass spectrometry assay for quantification ofmoexipril in human plasma. Analytes and the internal standard(stable labelled isotopes) from human plasma by using solidphase extraction technique with the help of Waters Oasis ® HLB 1 cc (30 mg) extraction cartridge. The reconstituted samples were chromatographed on Zorbax XDB C18,4.6*50mm column by using a mixture of acetonitrile -5 mM ammonium acetate buffer (80:20, v/v)as the mobile phase at a flow rate of 0.6 mL/min.The calibration curve obtained was linear (r 0.99) over the concentration range of 0.102-101.389 ng/mL for moexipril. Method validation was performed as per FDA guidelines and the results met the acceptance criteria. A run time of 2.2 min for each sample made it possible to analyze more than 350 human plasma samples per day.
{"title":"A simple,sensitive and rapid determination of moexipril in human plasma by a novel LC-MS/MS method using solid phase extraction technique","authors":"Vinayender Adireddy, V. Kommineni, V. Ponneri","doi":"10.20902/IJPTR.2019.120103","DOIUrl":"https://doi.org/10.20902/IJPTR.2019.120103","url":null,"abstract":"The aim of this work was to develop a simple,sensitive and selective liquid chromatography tandem mass spectrometry assay for quantification ofmoexipril in human plasma. Analytes and the internal standard(stable labelled isotopes) from human plasma by using solidphase extraction technique with the help of Waters Oasis ® HLB 1 cc (30 mg) extraction cartridge. The reconstituted samples were chromatographed on Zorbax XDB C18,4.6*50mm column by using a mixture of acetonitrile -5 mM ammonium acetate buffer (80:20, v/v)as the mobile phase at a flow rate of 0.6 mL/min.The calibration curve obtained was linear (r 0.99) over the concentration range of 0.102-101.389 ng/mL for moexipril. Method validation was performed as per FDA guidelines and the results met the acceptance criteria. A run time of 2.2 min for each sample made it possible to analyze more than 350 human plasma samples per day.","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82923755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20902/ijptr.2019.120304
P. Dudhe, H. Bhatt
Tuberculosis is one of the tenth primary cause of death throughout the world. The increasing number of drug resistance TB cases day by day and the patient poor compliance for the prolong treatment crating a alarming situation. The best tool to create the lead compounds for any disease is can only be achieved through the Combination of ligand and structure-based approaches. We have carried out comparative molecular field analysis(CoMFA) and comparative molecular similarity indices analysis (CoMSIA) on the reported series of Salicylanilide 4-(trifluoromethyl)benzoates&2-hydroxy-N-phenylbenzamides derivatives as Mycobacterium tuberculosis inhibitors. In CoMFA model, the cross validated q 2 and the noncross validated r 2 value for training set were found as0.643and 0.945, respectively; while in CoMSIA model, q 2 value was 0.819and r 2 value was 0.954. The generated contour maps (CoMFA & CoMSIA) fields were used for the design of 35 novel2 & 3-(4-aminobenzamido) benzoic acid derivatives and the prediction the pMIC of the design series were carried out. The series is also checked for the toxicity using osiris property explorer which could be explored in future to identify novel Mycobacterium tuberculosis inhibitors.
结核病是全世界第十大主要死因之一。耐药结核病病例日益增多，患者对延长治疗依从性差，情况令人担忧。创建任何疾病先导化合物的最佳工具只能通过结合配体和基于结构的方法来实现。我们对已报道的水杨酰苯胺4-(三氟甲基)苯甲酸酯和2-羟基- n -苯基苯酰胺衍生物作为结核分枝杆菌抑制剂进行了比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)。在CoMFA模型中，训练集的交叉验证q 2和非交叉验证r 2的值分别为0.643和0.945;CoMSIA模型的q2值为0.819,r2值为0.954。利用生成的等高线图(CoMFA和CoMSIA)区对35种新型2和3-(4-氨基苯甲胺)苯甲酸衍生物进行了设计，并对设计系列的pMIC进行了预测。该系列也检查了毒性使用osiris属性探索者，可以在未来探索，以确定新的结核分枝杆菌抑制剂。
{"title":"3D QSAR studies of Salicylanilide benzoates derivatives & generation of new leads as Mycobacterium tuberculosis inhibitors","authors":"P. Dudhe, H. Bhatt","doi":"10.20902/ijptr.2019.120304","DOIUrl":"https://doi.org/10.20902/ijptr.2019.120304","url":null,"abstract":"Tuberculosis is one of the tenth primary cause of death throughout the world. The increasing number of drug resistance TB cases day by day and the patient poor compliance for the prolong treatment crating a alarming situation. The best tool to create the lead compounds for any disease is can only be achieved through the Combination of ligand and structure-based approaches. We have carried out comparative molecular field analysis(CoMFA) and comparative molecular similarity indices analysis (CoMSIA) on the reported series of Salicylanilide 4-(trifluoromethyl)benzoates&2-hydroxy-N-phenylbenzamides derivatives as Mycobacterium tuberculosis inhibitors. In CoMFA model, the cross validated q 2 and the noncross validated r 2 value for training set were found as0.643and 0.945, respectively; while in CoMSIA model, q 2 value was 0.819and r 2 value was 0.954. The generated contour maps (CoMFA & CoMSIA) fields were used for the design of 35 novel2 & 3-(4-aminobenzamido) benzoic acid derivatives and the prediction the pMIC of the design series were carried out. The series is also checked for the toxicity using osiris property explorer which could be explored in future to identify novel Mycobacterium tuberculosis inhibitors.","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78085523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20902/ijptr.2019.120307
S. Saini, C. Majee, G. Chakraborthy, Salahuddin
Abstract : The objective of this review was to study the novel methods to the omeprazole synthesis and pharmaceutical impurities of proton pump inhibitors that provide an insight to researchers about the development of proton pump inhibitors. However, this paper emphasized on the study of various pharmaceutical impurities of anti-ulcer drug. The drug used for the study was omeprazole which is chemically known as (5-methoxy-2-[[(4-metboxy-3,5dimethylpyridinyl) methyl] sulfinyl]-l-benzimidazole) that inhibits gastric ATPase enzyme by oxidizingits sulfhydryl groups.The process involved during synthesis. The novel process come into existence due to incomplete oxidation of pyrmetazole and overoxidation to sulfone that leads to the formation of sulfone N-oxide. The procedure involved 5-methoxy thiobenzimidazole to the formation of an ester followed by coupling of the ester with the Grignard reagent of 2-chloromethyl-4-methoxy-3,5-dimethyl-pyridine. The novel synthesis process for pharmaceutical impurities achieve the expected yield and process observed to be short, simple. The synthesized impurity of proton pump inhibitors can be used as standard impurity, that can be utilized for further studied in various aspects. This review article will describe about the various novel impurities of omeprazole that available as marketed formulation.
{"title":"Novel Synthesis of Omeprazole and Pharmaceutical Impurities of Proton pump inhibitors : A Review","authors":"S. Saini, C. Majee, G. Chakraborthy, Salahuddin","doi":"10.20902/ijptr.2019.120307","DOIUrl":"https://doi.org/10.20902/ijptr.2019.120307","url":null,"abstract":"Abstract : The objective of this review was to study the novel methods to the omeprazole synthesis and pharmaceutical impurities of proton pump inhibitors that provide an insight to researchers about the development of proton pump inhibitors. However, this paper emphasized on the study of various pharmaceutical impurities of anti-ulcer drug. The drug used for the study was omeprazole which is chemically known as (5-methoxy-2-[[(4-metboxy-3,5dimethylpyridinyl) methyl] sulfinyl]-l-benzimidazole) that inhibits gastric ATPase enzyme by oxidizingits sulfhydryl groups.The process involved during synthesis. The novel process come into existence due to incomplete oxidation of pyrmetazole and overoxidation to sulfone that leads to the formation of sulfone N-oxide. The procedure involved 5-methoxy thiobenzimidazole to the formation of an ester followed by coupling of the ester with the Grignard reagent of 2-chloromethyl-4-methoxy-3,5-dimethyl-pyridine. The novel synthesis process for pharmaceutical impurities achieve the expected yield and process observed to be short, simple. The synthesized impurity of proton pump inhibitors can be used as standard impurity, that can be utilized for further studied in various aspects. This review article will describe about the various novel impurities of omeprazole that available as marketed formulation.","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81589184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20902/ijptr.2019.120302
W. Talaat, Mohamed M. Y. Kaddah
Herein, the potency, bioavailability and purity of sorafenib can be easily investigated in the presence of different degradation products through the present work. The bioanalysis of sorafenib in tablets and human plasma was achieved by a simple chromatographic procedure. The separation was conducted at room temperature using a stainless steel Hibar C 18 (150 X 4.6 mm i.d ). The analytes were detected with UV detector at 255 nm. A simple mobile phase of acetonitrile / phthalate Buffer / methanol (75: 24.5: 0.5, v/v) (pH 4) was eluted at a flow rate of 1.5 mL/ min. A rectilinear calibration curve was obtained over concentration range of 0.05 – 2.0 μg /mL, with a detection and quantification limits (LOD, LOQ) of 0.006 and 0.017 μg /mL respectively.
通过本研究，可以很容易地在不同降解产物的存在下研究索拉非尼的效价、生物利用度和纯度。索拉非尼片剂和人血浆的生物分析采用简单的色谱法。采用不锈钢Hibar c18 (150 X 4.6 mm i.d)在室温下进行分离。用紫外检测器检测，波长为255 nm。以乙腈/邻苯二甲酸酯缓冲液/甲醇(75:24.5:0.5,v/v) (pH 4)为简单流动相，以1.5 mL/ min的流速洗脱，在0.05 ~ 2.0 μg /mL范围内得到直线校准曲线，检出限(LOD)为0.006，定量限(LOQ)为0.017 μg /mL。
{"title":"Validated Analytical Method for the Determination of Sorafenib in Dosage form and Human plasma in presence of it Degradation Products","authors":"W. Talaat, Mohamed M. Y. Kaddah","doi":"10.20902/ijptr.2019.120302","DOIUrl":"https://doi.org/10.20902/ijptr.2019.120302","url":null,"abstract":"Herein, the potency, bioavailability and purity of sorafenib can be easily investigated in the presence of different degradation products through the present work. The bioanalysis of sorafenib in tablets and human plasma was achieved by a simple chromatographic procedure. The separation was conducted at room temperature using a stainless steel Hibar C 18 (150 X 4.6 mm i.d ). The analytes were detected with UV detector at 255 nm. A simple mobile phase of acetonitrile / phthalate Buffer / methanol (75: 24.5: 0.5, v/v) (pH 4) was eluted at a flow rate of 1.5 mL/ min. A rectilinear calibration curve was obtained over concentration range of 0.05 – 2.0 μg /mL, with a detection and quantification limits (LOD, LOQ) of 0.006 and 0.017 μg /mL respectively.","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"57 4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77750816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20902/ijptr.2019.120402
Nilam B Jadhav, S. Yadav, K. Gusain
Nimorazole is an antiprotozoal medicine used to treat infections caused by protozoa in the stomach, intestines, or genital areas. The main principle of this study was to develop RP-HPLC technique for the quantitative determination of Nimorazole in human plasma. The separation was accomplished by the isocratic method by using column C18 (Thermosil ODS), detection wavelength was 294 nm. The analyte was extracted in acetonitrile by liquid-liquid extraction. Acetonitrile: water in the ratio 30:70 was used as mobile phase for estimation of the drug in human plasma with a flow rate of 0.8 mL/min at a detection wavelength of 294 nm. Retention time was found to be 7.933 ± 0.23 min.The developed method was found to be linear over the concentration range of 60-360 μg/mL, with a correlation coefficient of 0.9991. The LOD and LOQ were found to be 10 μg/mL and 40 μg/mL, respectively. The method ensure for Precision and % RSD was found to be less than 2 % and the mean % recovery was found to be 99.58%. This method was effectively and favourably applied to the plasma samples and it seems to be appropriate tool for regular therapeutic drug monitoring of anti-infective drugs.
{"title":"Bioanalytical Method Development and Validation of\u0000Estimation of Nimorazole by RP-HPLC in Human Plasma","authors":"Nilam B Jadhav, S. Yadav, K. Gusain","doi":"10.20902/ijptr.2019.120402","DOIUrl":"https://doi.org/10.20902/ijptr.2019.120402","url":null,"abstract":"Nimorazole is an antiprotozoal medicine used to treat infections caused by protozoa in the stomach, intestines, or genital areas. The main principle of this study was to develop RP-HPLC technique for the quantitative determination of Nimorazole in human plasma. The separation was accomplished by the isocratic method by using column C18 (Thermosil ODS), detection wavelength was 294 nm. The analyte was extracted in acetonitrile by liquid-liquid extraction. Acetonitrile: water in the ratio 30:70 was used as mobile phase for estimation of the drug in human plasma with a flow rate of 0.8 mL/min at a detection wavelength of 294 nm. Retention time was found to be 7.933 ± 0.23 min.The developed method was found to be linear over the concentration range of 60-360 μg/mL, with a correlation coefficient of 0.9991. The LOD and LOQ were found to be 10 μg/mL and 40 μg/mL, respectively. The method ensure for Precision and % RSD was found to be less than 2 % and the mean % recovery was found to be 99.58%. This method was effectively and favourably applied to the plasma samples and it seems to be appropriate tool for regular therapeutic drug monitoring of anti-infective drugs.","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"41 4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82431675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20902/IJPTR.2019.120101
J. Chand, S. Sultana, G. Sekhar, D. Tony, N. R. Lakshmi, A. N. Babu, R. Nadendla
Alzheimer’s disease (AD) affects the central nervous system causing progressive degeneration of neurons, which affect cognitive function of the individual. So, the aim of this study was to identify the potential of aqueous and methanolic stem extracts of Securinega leucopyrus to be used as a therapeutic agent against Alzheimer’s disease. The cognitive impairment was produced by the methods, ethanolinduced cognitive impairment &diazepam induced amnesia. The potentials of the extracts were determined by using Morris water maze (MWM) test. Both the extracts showed significant learning and memory enhancement activity.
{"title":"Securinega leucopyrus improves Memory and Learning in Alzheimer’s Model: An Experimental Study in Rat","authors":"J. Chand, S. Sultana, G. Sekhar, D. Tony, N. R. Lakshmi, A. N. Babu, R. Nadendla","doi":"10.20902/IJPTR.2019.120101","DOIUrl":"https://doi.org/10.20902/IJPTR.2019.120101","url":null,"abstract":"Alzheimer’s disease (AD) affects the central nervous system causing progressive degeneration of neurons, which affect cognitive function of the individual. So, the aim of this study was to identify the potential of aqueous and methanolic stem extracts of Securinega leucopyrus to be used as a therapeutic agent against Alzheimer’s disease. The cognitive impairment was produced by the methods, ethanolinduced cognitive impairment &diazepam induced amnesia. The potentials of the extracts were determined by using Morris water maze (MWM) test. Both the extracts showed significant learning and memory enhancement activity.","PeriodicalId":14252,"journal":{"name":"International Journal of PharmTech Research","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85008841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：